Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/05/067423
CTRI/2024/05/067423
Recruiting
Phase 2

Clinical study to evaluate efficacy and safety of Vimosa softgel capsule in vaginal dryness and vaginal prolapse – An open label, single arm, multi-center, interventional, prospective, clinical study - NI

Abhinav Health Care Products Pvt Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Abhinav Health Care Products Pvt Ltd
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Abhinav Health Care Products Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •1\. Female subjects (21 to 70 years) with symptoms of vaginal dryness due to various causes including reduced secretory function of the vaginal epithelium, anti\-estrogen medications, hormonal therapy, use of scented or perfumed soaps, sprays and washes around or in vagina, removal of ovaries etc.
  • •2\. A negative urine pregnancy test for all female subjects unless patient has had a hysterectomy, tubal ligation, or is greater than 2 years post menopause.
  • •1 Females (30 to 60 years) with first or second degree uterovaginal prolapse
  • •2\.A negative urine pregnancy test for all female patients unless patient has had a hysterectomy, tubal ligation, or is greater than 2 years post menopause.

Exclusion Criteria

  • •1\. Patients with vaginal infections such as trichomonas, candida \& bacterial vaginosis (BV).
  • •2\. Subjects who are known cases of Diabetes having uncontrolled blood sugar levels (fasting blood sugar levels NMT 250 mg per dl and HbA1c NMT 8 percent)
  • •3\. Patients with breast cancer, uterine cancer and genital bleeding of unknown origin.
  • •4\. Patients using medications (internally and externally) that promote healing
  • •5\. History of Use of any other investigational product within 1 month prior to randomization
  • •6\. Known history of hypersensitivity to ingredients used in study product
  • •7\. Pregnant and breast\-feeding women
  • •1\. Patients with Procidentia, congenital elongation of cervix, cervical fibroid, polyp, chronic inversion of uterus.
  • •2\. Patients who have been advised to undergo surgical removal of uterus or surgical treatment for Utero\-vaginal prolapse
  • •3\. Subjects who are known cases of Diabetes having uncontrolled blood sugar levels (fasting blood sugar levels NMT 250 mg per dl and HbA1c NMT 8 percent)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Photodynamic diagnosis using 5-ALA for biliary pancreatic cancerBiliary pancreatic cancer
JPRN-jRCTs061210042Isomoto Hajime62
Not yet recruiting
Not Applicable
Efficacy and safety of Photodynamic diagnosis using aminolaevulinic acid for oral cancer patients.
JPRN-jRCTs031230192Satomura Kazuhito80
Completed
Phase 3
Efficacy and safety of Dapoxetine Hydrochloride Tablet in treatment of Premature Ejaculatio
CTRI/2010/091/000660Emcure Pharmaceuticals Ltd, Pune172
Unknown
Phase 3
Clinical trial of tablet containg two medicines - Dapoxetine and Sildenafil - for the treatment of co-existing Erectile Dysfunction and Premature Ejaculation.Health Condition 1: null- Co-existing Erectile Dysfunction and Premature Ejaculation
CTRI/2012/01/002370Emcure Pharmceuticals Ltd Pune200
Completed
Phase 3
Clinical Study to evaluate efficacy and safety of Eslicarbazepine acetate as an adjunctive therapy in partial-onset seizures
CTRI/2010/091/001194Emcure Pharmaceuticals Ltd., Pune200